DETERMINATION OF PHARMACOKINETIC PARAMETERS AND FACTORS INFLUENCING THE PHARMACOKINETIC PARAMETERS OF PHENYTOIN IN THAI CHILDREN WITH EPILEPSY

Authors

  • CHANRUANG A. Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand
  • RAKNGAM M. Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand
  • TEEKACHUNHATEAN S. Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  • DAENGSUEPTRAKUN K. Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand
  • PUNYAWUDHO B. Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand

DOI:

https://doi.org/10.22159/ijpps.2021v13i1.37178

Keywords:

Pharmacokinetic, Factors Influencing, Phenytoin, Epilepsy

Abstract

Objective: Phenytoin displays nonlinear pharmacokinetics due to the saturation of its’ metabolizing enzymes, thus making dosing adjustments a challenge in clinical practice. However, data on the pharmacokinetic parameters of phenytoin in pediatric patients with epilepsy in Thailand remain lacking. This study aimed to determine the pharmacokinetic parameters of phenytoin, and the factors influencing them in epileptic Thai children using therapeutic drug monitoring data.

Methods: Steady state phenytoin plasma concentrations were collected from 96 Thai children with epilepsy aged ≤ 15 y. For individuals having a single steady-state concentration (Css) on one dosage, the Vmax was determined by fixing Km = 4.5 mg/l. For patients with two values for Css with different dosages, the Ludden method was used to determine Vmax and Km. Influences on Vmax and Km by demographic factors including age, sex, weight, serum albumin, and the use of CYP2C9 inducers (carbamazepine, phenobarbital, folic acid, and vigabatrin) and inhibitors (valproic acid and topiramate) were determined by linear mixed-effects regression.

Results: The majority of patients had sub-therapeutic plasma concentrations of phenytoin. The Vmax and Km were estimated to be 9.84 mg/kg/d and 2.32 mg/l, respectively. Age and weight significantly influenced Vmax, whereas Km had no significant influencing factors.

Conclusion: The Vmax estimated in this study is different from other populations previously reported. Our results suggest that increased phenytoin dosages may be required to achieve optimal concentrations due to the sub-therapeutic concentrations reported here. The results from this study are beneficial for phenytoin dosage individualization in Thai children.

Downloads

Download data is not yet available.

References

Prasat Neurological Institute. Thai clinical practice guidelines for epilepsy; 2016. p. 10-99.

Lineweaver H, Burk D. The determination of enzyme dissociation constants. J Am Chem Soc 1934;56:658-66.

Suzuki Y, Mimaki T, Cox S, Koepke J, Hayes J, Walson PD. Phenytoin age-dose-concentration relationship in children. Ther Drug Monit 1994;16:145-50.

Omer QB, Hassan Y, Aziz N, Rashid M, Lin LAW. Pharmacokinetic study of phenytoin in Malaysian pediatric patients at penang hospital. Int J Pharm Pharm Sci 2010;2:98-101.

Valodia P, Seymour M, Miller R, McFadyen ML, Folb PI. Factors influencing the population pharmacokinetic parameters of phenytoin in adult epileptic patients in South Africa. Ther Drug Monit 1999;21:57-62.

El-Sayed YM, Islam SI. Phenytoin michaelis-menten pharmacokinetics in Saudi patients. Int J Clin Pharmacol Ther Toxicol 1989;27:173-8.

Salehifar E, Zohrabi M, Eshghi S, Saeedi M, Ebrahimi P. Different pharmacokinetic parameters of phenytoin in iranian outpatients: need to optimize the current dosage administration. Iran J Pharm Res 2010;8:37-45.

Ismail R, Rahman AF, Chand P. Pharmacokinetics of phenytoin in routine clinic patients in Malaysia. J Clin Pharm Ther 1994;19:245-8.

Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002;Suppl 3:53-9.

Abduljabbar M, Al-Khamis K, Ogunniyi A, Daif AK, Al-Yamani M. Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters. Eur J Neurol 1999;6:331-4.

Ludden TM, Allen JP, Valutsky WA, Vicuna AV, Nappi JM, Hoffman SF, et al. Individualization of phenytoin dosage regimens. Clin Pharmacol Ther 1977;21:287-93.

Yukawa E, Higuchi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan. J Clin Pharm Ther 1989;14:71-7.

Sharma S, Tabassum F, Dwivedi P, Agarwal R, Kushwaha S, Bala K, et al. Critical appraisal of serum phenytoin variation with patient characteristics in a North Indian population. Neurol India 2015;63:202-8.

Wisuttiwong P. Pharmacokinetic parameters of phenytoin in Thai epileptic children; 2007. p. 1-89.

Lietman PS, Chiba K, Ishizaki T, Miura H, Minagawa K. Michaelis-menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. J Pediatr 1980;96:479-84.

Garrettson LK, Jusko WJ. Diphenylhydantoin elimination kinetics in overdosed children. Clin Pharmacol Ther 1975; 17:481-91.

Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 2000;Suppl 3:S128-38.

Houghton GF, Richens A, Leighton M. Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. Br J Clin Pharmacol 1975;2:251-6.

Published

2021-01-01

How to Cite

A., C., R. M., T. S., D. K., and P. B. “DETERMINATION OF PHARMACOKINETIC PARAMETERS AND FACTORS INFLUENCING THE PHARMACOKINETIC PARAMETERS OF PHENYTOIN IN THAI CHILDREN WITH EPILEPSY”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 13, no. 1, Jan. 2021, pp. 47-51, doi:10.22159/ijpps.2021v13i1.37178.

Issue

Section

Short Communication(s)